E-52862
http://dbpedia.org/resource/E-52862 an entity of type: Thing
E-52862, also known as sigma-1 receptor antagonist (S1A, S1RA), as well as MR-309, is a selective sigma-1 receptor antagonist, with a reported binding affinity of Ki = 17.0 ± 7.0 nM, selective over the sigma-2 receptor and against a panel of other 170 receptors, enzymes, transporters and ion channels. In preclinical studies, S1RA has demonstrated efficacy in relieving neuropathic pain and pain in other sensitizing conditions, associated with an improvement of the emotional negative state.
rdf:langString
rdf:langString
E-52862
xsd:integer
37326921
xsd:integer
1120770946
xsd:integer
20
xsd:integer
878141
xsd:integer
2170062
xsd:integer
28641653
xsd:integer
23
xsd:integer
4
xsd:integer
3
xsd:integer
2
rdf:langString
CC1=CC=NN1C1=CC=C2C=CC=CC2=C1
xsd:integer
1
rdf:langString
DGPGXHRHNRYVDH-UHFFFAOYSA-N
rdf:langString
S1A; S1RA; MR-309
rdf:langString
ZW18DSD1H4
xsd:integer
165
rdf:langString
E-52862, also known as sigma-1 receptor antagonist (S1A, S1RA), as well as MR-309, is a selective sigma-1 receptor antagonist, with a reported binding affinity of Ki = 17.0 ± 7.0 nM, selective over the sigma-2 receptor and against a panel of other 170 receptors, enzymes, transporters and ion channels. In preclinical studies, S1RA has demonstrated efficacy in relieving neuropathic pain and pain in other sensitizing conditions, associated with an improvement of the emotional negative state. S1RA is being developed by Esteve for the treatment of neuropathic pain and the potentiation of opioid analgesia and has successfully completed Phase I clinical trials showing good safety and tolerability, and a pharmacokinetic profile compatible with once a day oral administration. Phase II clinical trials are currently underway, making S1RA the first selective sigma-1 receptor antagonist evaluated in humans for these conditions.
xsd:nonNegativeInteger
5859
xsd:string
878141-96-9
xsd:string
2170062
xsd:string
ZW18DSD1H4